Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03261999
• Date of registration: 19/08/2017
• Prospective Registration: Yes
• Primary sponsor: Foresee Pharmaceuticals Co., Ltd.
• Public title: Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
• Scientific title: An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
• Date of first enrolment: September 26, 2017
• Target sample size: 144
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03261999
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 3

Countries of recruitment

Czechia, Korea, Republic of, Lithuania, Slovakia, United States

Contacts

• Name: John Mao, PhD
• Affiliation: Foresee Pharmaceuticals Co., Ltd.

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Males aged = 18 years old

2. Males with histologically confirmed carcinoma of the prostate

3. Subjects who are judged by the attending physician and/or Principal Investigator to be
a candidate for androgen ablation therapy

4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit

5. Eastern Cooperative Oncology Group (ECOG) Performance score = 2

6. Life expectancy of at least 18 months

7. Laboratory values

- Absolute neutrophil count = 1,500 cells/µL

- Platelets = 100,000 cells/µL

- Hemoglobin = 10 gm/dL

- Total bilirubin = 1.5 × upper limit of normal (ULN)

- AST (SGOT) = 2.5 × ULN

- ALT (SGPT) = 2.5 × ULN

- Serum creatinine = 1.5 mg/dL

- Lipid profile within acceptable range according to investigator's opinion

- Serum glucose within acceptable range according to investigator's opinion

- HgbA1c within acceptable range according to investigator's opinion

- Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to
investigator's judgment

- Serum glucose within acceptable range according to investigator's judgement

- Urinalysis within normal range according to the investigator's judgment

8. Agree to use male contraceptive methods during study trial

9. Based on the Investigator's judgment, the ability to understand the nature of the
study and any hazards of participation, and to communicate satisfactorily with the
Investigator and to participate in, and to comply with, the requirements of the entire
protocol

10. All aspects of the protocol explained and written informed consent obtained

Exclusion Criteria:

1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen
therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of
carcinoma of the prostate. Radiation for pain control will be allowed during the
study.

2. Receipt of any vaccination (including influenza) within 4 weeks of screening visit

3. History of blood donation within 2 months of screening visit

4. History of anaphylaxis to any LH-RH analogues

5. Receipt of any LHRH suppressive therapy within 6 months of screening visit

6. Major surgery, including any prostatic surgery, within 4 weeks of screening visit

7. History and concomitant clinical and radiographic evidence of central nervous
system/spinal cord metastases and subjects at risk for spinal cord compression

8. Clinical evidence of active urinary tract obstruction and subjects at risk for urinary
obstruction

9. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy

10. History or presence of hypogonadism, or receipt of exogenous testosterone
supplementation within 6 months of Baseline

11. Clinically significant abnormal ECG and/or history of clinically significant
cardiovascular disease as judged by the investigator

12. History of drug and/or alcohol abuse within 6 months of Baseline

13. Contraindication to leuprolide or an LHRH agonist as indicated on package labeling

14. Use of 5-alpha reductase inhibitor within the last 6 months of screening visit

15. History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well
controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are
required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac >
9.5% or urine glycosuria > 1.0 g/dL should be excluded.

16. Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens

17. Use of any investigational agent within 4 weeks of screening visit

18. Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except
for those listed in the permitted Concomitant Treatment section.

19. Uncontrolled intercurrent illness that would jeopardize the subject's safety,
interfere with the objectives of the protocol, or limit the subject's compliance with
study requirements, as determined by the Investigator in consultation with the Sponsor



Age minimum: 18 Years
Age maximum: N/A
Gender: Male

Health Condition(s) or Problem(s) studied

Prostatic Neoplasms

Intervention(s)

Drug: Leuprolide Mesylate

Primary Outcome(s)

Efficacy of Leuprolide Mesylate (LMIS 25mg) [Time Frame: 168 days]

Secondary Outcome(s)

Number of Participants With Adverse Events [Time Frame: 168 days]

Secondary ID(s)

2017-001333-88

FP01C-17-001

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 04/05/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT03261999